The genetic variation rs6903956 in the novel androgen-dependent tissue factor pathway inhibitor regulating protein (ADTRP) gene is not associated with levels of plasma coagulation factors in the Singaporean Chinese

Abstract

BackgroundGenome-wide association study (GWAS) has reported that rs6903956 within the first intron of androgen-dependent tissue factor pathway inhibitor (TFPI) regulating protein (ADTRP) gene is associated with coronary artery disease (CAD) risk in the Chinese population. Although ADTRP is believed to be involved in the upregulation of TFPI, the underlying mechanism involved is largely unknown. This study investigated the association of rs6903956 with plasma Factor VII coagulant activity (FVIIc) and fibrinogen levels, which are regulated by TFPI and are independent risk predictors for CAD.MethodsWe conducted the analysis in both Chinese adult (N = 309) and neonatal cohorts (N = 447). The genotypes of the rs6903956 single nucleotide polymorphism (SNP) were determined by the polymerase chain reaction restriction fragment length polymorphism method (PCR–RFLP). FVIIc and fibrinogen level were measured from citrated plasma. The association between rs6903956 and coagulation factors was tested by linear regression with adjustment for possible confounders. Analysis was carried out in adults and neonates separately.ResultsNo significant association was observed between rs6903956 and plasma FVIIc nor fibrinogen levels with adjustment for age, gender, body mass index (BMI) and cigarette smoking in adults (P for FVIIc = 0.464; P for fibrinogen = 0.349). The SNP was also not associated with these two coagulation factors in the neonates (P for FVIIc = 0.579; P for fibrinogen = 0.359) after adjusting for gestational age, gender and birth weight.ConclusionsSNP rs6903956 on ADTRP gene was not associated with plasma FVIIc nor fibrinogen levels.

Periodontal therapy increases neutrophil extracellular trap degradation

“…Our findings are in line with previously reported improved ACVD clinical parameters such as systolic blood pressure and triglycerides. 12 , 13 This suggests that non-surgical periodontal treatment synergistically affects ACVD profiles, periodontal inflammatory parameters and NET degradation. Unraveling NET formation and degradation mechanisms in periodontitis patients may improve the understanding of the pathophysiology of periodontitis and the aetiopathogenetic links between periodontitis and its systemic co-morbidities such as ACVD, while also enabling the development of new therapeutic approaches.…”

“… 6 , 7 Nevertheless, previous research has shown beneficial effects of non-surgical periodontal therapy on several clinical and biochemical parameters of ACVD, including flow-mediated dilatation, intima media thickness, systolic blood pressure, and a decrease in activated platelets. 8 – 14 Altogether, this may reduce the risk factors of an ACVD profile of periodontitis patients.…”

Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice

“…Available perioperative data are principally generated from RCT substudies and considering the DOAC pharmacokinetics parameters (short time to peak effect and short half-life), periprocedural bridging is usually not required ( Dubois et al, 2017 ). However, decisions in elective situations about stopping DOACs perioperatively should be based on the thromboembolic risk of the patient as well as general characteristics, the bleeding risk of the invasive procedures, and the DOAC pharmacokinetics profile.…”